[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"AJU Pharm Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":144},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,60,84,104,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100643125","phase-1-bioequivalence-study-of-aju-g721-and-g721r-in-healthy-adult-volunteers-under-fasting-conditions-100643125",false,"NCT07643220","Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fasting Conditions","An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of \"AJU-G721\" and \"G721R\" in Healthy Adult Male Subjects","Inclusion Criteria:\n\n* Healthy male adults aged ≥19 years and \\\u003C55 years at screening.\n* Body weight ≥ 50 kg and body mass index (BMI) between 18 and 30 kg\u002Fm².\n* Clinically healthy based on medical history, physical examination, ECG, and laboratory test results, as determined by the investigator.\n* Willing and able to provide written informed consent.\n* Agrees to use medically acceptable contraception during the required study period.\n\nExclusion Criteria:\n\n* Use of medications known to induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose, or other medications that may interfere with the study within 10 days prior to dosing.\n* Participation in another clinical trial involving an investigational product within 6 months prior to the first dose.\n* Whole blood donation within 8 weeks or component blood donation within 2 weeks prior to the first dose.\n* History of gastrointestinal resection that may affect drug absorption.\n* Known hypersensitivity to dutasteride, tamsulosin, or any component of the investigational product.\n* History of psychiatric illness, or any condition considered unsuitable for study participation by the investigator.",true,"MALE","19 Years","54 Years",{"count":21,"type":22},44,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","To evaluate and compare the safety and pharmacokinetic profiles of \"AJU-G721\" (test drug) and \"G721R\" (reference drug) in healthy adult male subjects.",[28],"Moderate-to-severe Benign Prostatic Hyperplasia (BPH)","RECRUITING","2026-06-10",{"date":32,"type":33},"2026-06-12","ACTUAL",{"date":35,"type":22},"2026-06",{"date":37,"type":22},"2026-07",{"name":39,"class":40},"AJU Pharm Co., Ltd.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":50,"briefSummary":26,"conditions":51,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":57,"leadSponsor":59,"locationsCount":41},"100643505","phase-1-bioequivalence-study-of-aju-g721-and-g721r-in-healthy-adult-volunteers-under-fed-conditions-100643505","NCT07643233","Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fed Conditions","An Open-Label, Randomized, Fed, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of \"AJU-G721\" and \"G721R\" in Healthy Adult Male Subjects",{"count":49,"type":22},36,[25],[28],"NOT_YET_RECRUITING","2026-06-08",{"date":55,"type":33},"2026-06-11",{"date":37,"type":22},{"date":58,"type":22},"2026-08",{"name":39,"class":40},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":16,"sex":67,"minAge":18,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":23,"phases":71,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":41},"100638182","phase-1-bioequivalence-study-of-aju-c715-and-c715r-in-healthy-adult-volunteers-100638182","NCT07581028","Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers","An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of \"AJU-C715\" and \"C715R\" in Healthy Adult Volunteers","Inclusion Criteria:\n\n1. Healthy adults aged 19 to less than 60 years at the time of screening\n2. Weight ≥ 50 kg for men or ≥ 45 kg for women, with a calculated body mass index(BMI) of 18 to 30 kg\u002Fm² at the time of screening.\n3. Those who have no congenital chronic disease or chronic disease requiring treatment and who have no pathological symptoms or findings.\n4. Those who are eligible for the clinical trial based on laboratory test results(hematology, blood chemistry, serum, and urine tests) and 12-lead ECG findings during screening.\n5. Those who voluntarily decide to participate and agree to comply with the cautions after hearing and fully understanding the detailed description of this clinical trial.\n6. Those who agree to use highly effective methods of contraception(excluding hormonal methods) to prevent pregnancy, either for themselves or their spouse\u002Fpartner, from the first administration of the investigational medicinal product until one week after the last administration, and who agree not to donate sperm or eggs during this period.\n\nExclusion Criteria:\n\n1. Those who take barbiturate and related (causing induction or inhibition of metabolism) drug within 1 month or the first administration of clinical trial drug within 10 days.\n2. Those who received investigational product or bioequivalence test drug within 6 months before the first administration of clinical trial drug. 3. Those who donated whole blood within 8 weeks, received apheresis within 2 weeks, blood transfusion within 1 month or can't refrain from donating blood from the time of written consent until the end of the study.\n\n4\\. Those who has a history of gastrointestinal disease or surgery which may affect the absorption of the drug.\n\n5\\. Those who exceeding an alcohol consumption criteria Alcohol: Men - 21 glass\u002Fweek, Women - 14 glass\u002Fweek (1 glass: Soju 50 mL, Beer 250mL or liquor: 30mL), Smoke: 20 cigarettes\u002Fday.\n\n6\\. Those who has under\n\n* Those who are hypersensitive to component of the Investigational product and have the medical history\n* Those with active liver disease or persistent elevation of aminotransferase levels of unknown\n* Those taking cyclosporin\n* Those with Myopathy\n* Those with severe Renal Impairment due to Renal Failure\n* Those who has Genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption 7. Those who has a history of mental illness. 8. Those who are deemed unfit by the investigators to participate in the clinical trial for other reasons.\n\n  9\\. Women who are pregnant or who may be pregnant and breastfeed.","ALL","59 Years",{"count":70,"type":22},60,[25],"To Evaluate the Safety and Pharmacokinetics of \"AJU-C715\" and \"C715R\" in Healthy Adults.",[74,75],"Hypercholerolemia","Dyslipidemia","2026-05-06",{"date":78,"type":33},"2026-05-12",{"date":80,"type":22},"2026-08-07",{"date":82,"type":22},"2026-08-24",{"name":39,"class":40},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":16,"sex":67,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":103,"locationsCount":41},"100610767","phase-1-bioequivalence-study-of-aju-r713-and-r713r-in-healthy-adult-volunteers-100610767","NCT07231861","Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers","An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of \"AJU-R713\" and \"R713R\" in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adults aged 19 years or older at the time of screening.\n* Body mass index (BMI) between 18 and 30 kg\u002Fm².\n\n  * Male subjects: body weight ≥ 50 kg.\n  * Female subjects: body weight ≥ 45 kg.\n* Clinically healthy based on medical history, physical examination, vital signs, electrocardiogram (ECG), and laboratory test results, as determined by the investigator.\n* Willing and able to provide written informed consent after receiving a full explanation of the study.\n* Subjects (and their partners, if applicable) agree to use highly effective, non-hormonal contraception from the first dosing day until one week after the last dose.\n\nExclusion Criteria:\n\n* Use of drugs known to induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose, or any medication likely to interfere with the study within 10 days prior to dosing.\n* Participation in any clinical trial involving investigational products within 6 months prior to the first dose.\n* Whole blood donation within 8 weeks, or component blood donation within 2 weeks prior to the first dose.\n* History of gastrointestinal surgery that may affect drug absorption (excluding appendectomy and hernia repair).\n* Known hypersensitivity to the investigational product or its components.\n* Known metabolic or genetic disorders such as galactose intolerance, lactase deficiency, glucose-galactose malabsorption, or phenylketonuria.\n* History of clinically significant psychiatric illness.\n* Pregnant or breastfeeding women, or women with a possibility of pregnancy.",{"count":70,"type":22},[25],"To Evaluate the Safety and Pharmacokinetics of Pranlukast hydrate in Healthy Adults.",[95,96],"Bronchial Asthma","Perennial Allergic Rhinitis","2025-11-16",{"date":99,"type":33},"2025-11-19",{"date":101,"type":22},"2025-12",{"date":101,"type":22},{"name":39,"class":40},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":16,"sex":67,"minAge":18,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":41},"100596385","phase-1-a-study-to-evaluate-the-safety-and-pharmacokinetics-of-dapagliflozin-linagliptin-and-metformin-in-healthy-adults-fed-state-study-100596385","NCT07044765","A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study","An Open-label, 2-arm, Single-sequence, Fed, Single Oral Dosing, Crossover Clinical Trial to Evaluate Safety and the Pharmacokinetics Between Dapagliflozin, Linagliptin and Metformin in Healthy Adult Subjects","Inclusion Criteria:\n\n* Healthy adult volunteers aged 19 to 50 years at the time of screening.\n* Body mass index (BMI) between 18.0 and 30.0 kg\u002Fm², inclusive.\n\n  * Male subjects must weigh ≥50 kg.\n  * Female subjects must weigh ≥45 kg.\n* No clinically significant congenital or chronic diseases requiring treatment, based on medical history and physical examination.\n* Clinically acceptable results from laboratory tests (e.g., hematology, biochemistry, serology, urinalysis) and electrocardiogram (ECG) at screening, as determined by the investigator.\n* Willing to use medically accepted contraception (excluding hormonal methods) from the first dose until 7 days after the last dose, and agrees not to donate sperm or eggs during this period.\n* Able and willing to provide written informed consent after receiving a full explanation of the study.\n\nExclusion Criteria:\n\n* Use of drugs known to induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose, or any medication likely to interfere with the study within 10 days prior to dosing.\n* Participation in any clinical trial involving investigational products within 6 months prior to the first dose.\n* Whole blood donation within 8 weeks, or component blood donation within 2 weeks prior to the first dose.\n* History of gastrointestinal surgery that may affect drug absorption (excluding appendectomy and hernia repair).\n* History of excessive alcohol consumption within 1 month prior to the first dose:\n\n  * \\>21 drinks\u002Fweek for males, \\>14 drinks\u002Fweek for females (1 drink = 50 mL soju, 30 mL whiskey, or 250 mL beer)\n* Known hypersensitivity to any component of the investigational product.\n* Clinically significant renal, hepatic, cardiovascular, respiratory, metabolic, or infectious diseases, including but not limited to:\n\n  * Moderate to severe renal impairment (eGFR or creatinine clearance \\\u003C45 mL\u002Fmin)\n  * Dialysis\n  * Acute or unstable heart failure\n  * Acute myocardial infarction, septicemia, or shock\n  * Type 1 diabetes, metabolic acidosis, or history of diabetic ketoacidosis\n  * Major surgery planned during the study (except minor procedures not affecting food or fluid intake)\n  * Severe infections, trauma, or nutritional deficiencies\n* Positive pregnancy test or currently breastfeeding (for female subjects).\n* History of significant psychiatric illness.\n* Determined by the investigator to be unsuitable for the study for any other reason.","50 Years",{"count":113,"type":22},32,[25],"To Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults after taking the drugs with food (fed state).",[117],"Type2 Diabetes Mellitus","2025-06-26",{"date":120,"type":33},"2025-07-01",{"date":122,"type":22},"2025-08",{"date":124,"type":22},"2025-11",{"name":39,"class":40},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":16,"sex":67,"minAge":18,"maxAge":111,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":143,"locationsCount":41},"100595617","phase-1-a-study-to-evaluate-the-safety-and-pharmacokinetics-of-dapagliflozin-linagliptin-and-metformin-in-healthy-adults-100595617","NCT07034781","A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults","An Open-label, 2-arm, Single-sequence, Single Oral Dosing, Crossover Clinical Trial to Evaluate Safety and the Pharmacokinetics Between Dapagliflozin, Linagliptin and Metformin in Healthy Adult Subjects","Inclusion Criteria:\n\n* Healthy adult volunteers aged 19 to 50 years at the time of screening.\n* Body mass index (BMI) between 18.0 and 30.0 kg\u002Fm², inclusive.\n\n  * Male subjects must weigh ≥50 kg.\n  * Female subjects must weigh ≥45 kg.\n* No clinically significant congenital or chronic diseases requiring treatment, based on medical history and physical examination.\n* Clinically acceptable results from laboratory tests (e.g., hematology, biochemistry, serology, urinalysis) and electrocardiogram (ECG) at screening, as determined by the investigator.\n* Willing to use medically accepted contraception (excluding hormonal methods) from the first dose until 50 days after the last dose, and agrees not to donate sperm or eggs during this period.\n* Able and willing to provide written informed consent after receiving a full explanation of the study.\n\nExclusion Criteria:\n\n* Use of drugs known to induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose, or any medication likely to interfere with the study within 10 days prior to dosing.\n* Participation in any clinical trial involving investigational products within 6 months prior to the first dose.\n* Whole blood donation within 8 weeks, or component blood donation within 2 weeks prior to the first dose.\n* History of gastrointestinal surgery that may affect drug absorption (excluding appendectomy and hernia repair).\n* History of excessive alcohol consumption within 1 month prior to the first dose:\n\n  * \\>21 drinks\u002Fweek for males, \\>14 drinks\u002Fweek for females (1 drink = 50 mL soju, 30 mL whiskey, or 250 mL beer)\n* Known hypersensitivity to any component of the investigational product.\n* Clinically significant renal, hepatic, cardiovascular, respiratory, metabolic, or infectious diseases, including but not limited to:\n\n  * Moderate to severe renal impairment (eGFR or creatinine clearance \\\u003C45 mL\u002Fmin)\n  * Dialysis\n  * Acute or unstable heart failure\n  * Acute myocardial infarction, septicemia, or shock\n  * Type 1 diabetes, metabolic acidosis, or history of diabetic ketoacidosis\n  * Major surgery planned during the study (except minor procedures not affecting food or fluid intake)\n  * Severe infections, trauma, or nutritional deficiencies\n* Positive pregnancy test or currently breastfeeding (for female subjects).\n* History of significant psychiatric illness.\n* Determined by the investigator to be unsuitable for the study for any other reason.",{"count":134,"type":22},50,[25],"To Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults",[117],"2025-06-20",{"date":140,"type":33},"2025-06-24",{"date":122,"type":22},{"date":124,"type":22},{"name":39,"class":40},""]